Overview
Takayuki Harada practices in Tokyo, Japan. Mr. Harada is rated as a Distinguished expert by MediFind in the treatment of Glaucoma. His top areas of expertise are Ganglion Cyst, Glaucoma, Ocular Hypertension (OHT), Optic Neuritis, and Vitrectomy.
His clinical research consists of co-authoring 105 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 35 articles in the study of Glaucoma.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Ganglion CystMr. Harada isElite. Learn about Ganglion Cyst.
- Distinguished
- GlaucomaMr. Harada isDistinguished. Learn about Glaucoma.
- Ocular Hypertension (OHT)Mr. Harada isDistinguished. Learn about Ocular Hypertension (OHT).
- Advanced
- Late-Onset Retinal DegenerationMr. Harada isAdvanced. Learn about Late-Onset Retinal Degeneration.
- Optic NeuritisMr. Harada isAdvanced. Learn about Optic Neuritis.
- Experienced
- CACH SyndromeMr. Harada isExperienced. Learn about CACH Syndrome.
- COVID-19Mr. Harada isExperienced. Learn about COVID-19.
- Diabetic RetinopathyMr. Harada isExperienced. Learn about Diabetic Retinopathy.
- Drug Induced DyskinesiaMr. Harada isExperienced. Learn about Drug Induced Dyskinesia.
- HypotoniaMr. Harada isExperienced. Learn about Hypotonia.
- Metabolic SyndromeMr. Harada isExperienced. Learn about Metabolic Syndrome.